Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05895266 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers
A Phase 1 study of Healthy Volunteer, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05895266 is a Phase 1 study of Healthy Volunteer that has completed, run by AbbVie. The registered enrollment target is 24 participants, below the 202-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05895266, a Phase 1 study of Healthy Volunteer, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The main objective of this study is to assess the drug-drug interaction and pharmacokinetics of ABBV-903 and Midazolam in healthy adult participants.
Conditions Studied
Interventions
- DRUG Midazolam
- DRUG ABBV-903
Study Locations (1)
Illinois
- Acpru /Id# 254970 - Grayslake
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-06-23 |
| Est. Completion | 2023-11-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05895266
The ClinicalTrials.gov registry entry for NCT05895266 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 202-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (88% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Volunteer appearing as the primary indexed condition, and to 2 interventions - of which Midazolam is the first listed.
NCT05895266 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05895266 about?
NCT05895266 is a clinical study titled "A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers". The main objective of this study is to assess the drug-drug interaction and pharmacokinetics of ABBV-903 and Midazolam in healthy adult participants.
What is the current status of trial NCT05895266?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2023-06-23. Estimated completion is 2023-11-02.
What conditions does trial NCT05895266 study?
This clinical trial studies the following conditions: Healthy Volunteer.
What interventions are being tested in trial NCT05895266?
The interventions under investigation include: Midazolam (DRUG), ABBV-903 (DRUG).
Who is sponsoring clinical trial NCT05895266?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05895266 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Healthy Volunteer Study
RECRUITING · Phase 1
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Role of Metal Ion Transporter ZIP8 in Alcohol-Related Behaviors
RECRUITING · Phase 1
-
A First-in-Human Single and Multiple Ascending Dose Study of MT-201
RECRUITING · Phase 1
-
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
RECRUITING · Phase 1
-
A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.